Our top pick for
Seelos Therapeutics, Inc is a biotechnology business based in the US. Seelos Therapeutics shares (SEEL) are listed on the NASDAQ and all prices are listed in US Dollars. Seelos Therapeutics employs 8 staff and has a market cap (total outstanding shares value) of USD$44.7 million.
|52-week range||USD$0.4195 - USD$1.705|
|50-day moving average||USD$0.8367|
|200-day moving average||USD$0.9574|
|Wall St. target price||USD$8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.812|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Seelos Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Seelos Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Seelos Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Seelos Therapeutics shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$375,000|
|Return on assets TTM||-121.91%|
|Return on equity TTM||-273.59%|
|Market capitalisation||USD$44.7 million|
TTM: trailing 12 months
There are currently 398,128 Seelos Therapeutics shares held short by investors – that's known as Seelos Therapeutics's "short interest". This figure is 8.1% up from 368,461 last month.
There are a few different ways that this level of interest in shorting Seelos Therapeutics shares can be evaluated.
Seelos Therapeutics's "short interest ratio" (SIR) is the quantity of Seelos Therapeutics shares currently shorted divided by the average quantity of Seelos Therapeutics shares traded daily (recently around 1.0 million). Seelos Therapeutics's SIR currently stands at 0.38. In other words for every 100,000 Seelos Therapeutics shares traded daily on the market, roughly 380 shares are currently held short.
However Seelos Therapeutics's short interest can also be evaluated against the total number of Seelos Therapeutics shares, or, against the total number of tradable Seelos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Seelos Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Seelos Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.008% of the tradable shares (for every 100,000 tradable Seelos Therapeutics shares, roughly 8 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Seelos Therapeutics.
Find out more about how you can short Seelos Therapeutics stock.
We're not expecting Seelos Therapeutics to pay a dividend over the next 12 months.
Seelos Therapeutics's shares were split on a 1:30 basis on 24 January 2019. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Seelos Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Seelos Therapeutics shares which in turn could have impacted Seelos Therapeutics's share price.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Everything we know about the WorldRemit IPO, plus information on how to buy in.
Everything we know about the Jowell Global IPO, plus information on how to buy in.
Steps to owning and managing AIRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing ACER, with 24-hour and historical pricing before you buy.
Steps to owning and managing WST, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRNA, with 24-hour and historical pricing before you buy.
Steps to owning and managing OLED, with 24-hour and historical pricing before you buy.
Steps to owning and managing RARE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TRVI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.